Enzalutamide has previously been FDA-approved for treatment of metastatic castration-resistant prostate cancer (mCRCP) and non-metastatic castration-resistant prostate cancer (nmCRPC).

After treatment, 65 percent of men in study had no signs of cancer after one year.

The treatment landscape for metastatic prostate cancer is shifting and expanding yet again, according to new findings from two large clinical trials presented at the American Society of Clinical Oncology.

Some men are more likely to be diagnosed with prostate cancer depending on two factors, according to research presented at the 2019 National Cancer Research Institute Conference.

Phase 3 clinical trial results demonstrate significant efficacy of the PARP-inhibitor for olaparib in advanced prostate cancer patients with specific tumor mutations